Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Common Equity (2021 - 2025)

Prime Medicine's Common Equity history spans 5 years, with the latest figure at $120.9 million for Q4 2025.

  • For Q4 2025, Common Equity fell 21.08% year-over-year to $120.9 million; the TTM value through Dec 2025 reached $120.9 million, down 21.08%, while the annual FY2025 figure was $120.9 million, 21.08% down from the prior year.
  • Common Equity reached $120.9 million in Q4 2025 per PRME's latest filing, down from $161.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $316.3 million in Q4 2022 to a low of -$223.1 million in Q3 2022.
  • Average Common Equity over 5 years is $86.7 million, with a median of $143.1 million recorded in 2023.
  • The largest YoY upside for Common Equity was 302.43% in 2022 against a maximum downside of 136.29% in 2022.
  • A 5-year view of Common Equity shows it stood at -$156.2 million in 2021, then soared by 302.43% to $316.3 million in 2022, then plummeted by 57.92% to $133.1 million in 2023, then grew by 15.09% to $153.1 million in 2024, then dropped by 21.08% to $120.9 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Common Equity are $120.9 million (Q4 2025), $161.8 million (Q3 2025), and $60.9 million (Q2 2025).